Literature DB >> 14749400

Statins for primary prevention: strategic options to save lives and money.

James Shepherd1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14749400      PMCID： PMC1079291          DOI： 10.1177/014107680409700205

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  21 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts).

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2003-08

3.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.

Authors:  D Wood; G De Backer; O Faergeman; I Graham; G Mancia; K Pyörälä
Journal:  Atherosclerosis       Date:  1998-10       Impact factor: 5.162

4.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

5.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

Review 6.  Debate: at what level of coronary heart disease risk should a statin be prescribed?

Authors:  P R Jackson; L E Ramsay
Journal:  Curr Opin Lipidol       Date:  2000-08       Impact factor: 4.776

7.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.

Authors:  Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier
Journal:  JAMA       Date:  2002-06-26       Impact factor: 56.272

8.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

Authors:  J Stamler; D Wentworth; J D Neaton
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

9.  Environmental health: problems and prospects.

Authors:  G Rose
Journal:  J R Coll Physicians Lond       Date:  1991-01

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321
View more
  1 in total

1.  Fixed-dose combination therapy--is it time for this approach to hypertension and dyslipidemia management?

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.